These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 4855448)

  • 21. Quality assurance for medical products: unified program for all federal agencies.
    Flaherty FJ
    Hosp Formul; 1976 Dec; 11(12):669, 674, 679. PubMed ID: 1028796
    [No Abstract]   [Full Text] [Related]  

  • 22. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WHO to set up international task force on counterfeit drugs.
    Zarocostas J
    BMJ; 2006 Feb; 332(7539):444. PubMed ID: 16497756
    [No Abstract]   [Full Text] [Related]  

  • 24. Counterfeit drugs: implications for health.
    ten Ham M
    Adverse Drug React Toxicol Rev; 1992; 11(1):59-65. PubMed ID: 1606284
    [No Abstract]   [Full Text] [Related]  

  • 25. Assuring total drug quality.
    Simmons HE
    J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621
    [No Abstract]   [Full Text] [Related]  

  • 26. [70 years of the State Institute for Drug Control].
    Drábek P; Hanzlícek Z
    Cesk Farm; 1988 Sep; 37(7):331-5. PubMed ID: 3058327
    [No Abstract]   [Full Text] [Related]  

  • 27. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 2008; (948):1-138. PubMed ID: 18557474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries].
    Burow W; Lüllmann H
    Schriftenr Geb Off Gesundheitswes; 1971; 31():1-64. PubMed ID: 5153578
    [No Abstract]   [Full Text] [Related]  

  • 29. [Quality control in the pharmaceutical industry].
    Bretscher E
    Pharm Acta Helv; 1972; 47(11):664-75. PubMed ID: 4657535
    [No Abstract]   [Full Text] [Related]  

  • 30. [Guidelines for introducing new drugs for medical use in Poland and control of their quality].
    Danysz A
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1673-4. PubMed ID: 6522321
    [No Abstract]   [Full Text] [Related]  

  • 31. Basis for the assurance of safety, quality and efficacy of medicines in Ireland.
    Scott AI
    Ir Med J; 1985 Dec; 78(12):361-4. PubMed ID: 4086258
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale drug therapy: reasons for failure and suggestions for its implementation.
    Mathur GP; Kushwaha KP; Mathur S
    Indian Pediatr; 1993 Jun; 30(6):815-8. PubMed ID: 7726879
    [No Abstract]   [Full Text] [Related]  

  • 33. Inspections: the international regulatory view--Japan.
    Kamura S
    PDA J Pharm Sci Technol; 1994; 48(4):182-3. PubMed ID: 7804816
    [No Abstract]   [Full Text] [Related]  

  • 34. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality control of pharmaceutical preparations and the Third World.
    Summers RS
    Cent Afr J Med; 1983 Dec; 29(12):247-9. PubMed ID: 6671214
    [No Abstract]   [Full Text] [Related]  

  • 36. [Separate drug control agencies united in a new, single organization].
    Forsberg B
    Lakartidningen; 1971 Apr; 68(15):1698-701. PubMed ID: 5577238
    [No Abstract]   [Full Text] [Related]  

  • 37. Substandard and counterfeit medicines.
    Rassool GH
    J Adv Nurs; 2004 May; 46(3):338-9. PubMed ID: 15119344
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
    Griffiths E; Thorpe R; Wadhwa M; Sohn Y
    Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898
    [No Abstract]   [Full Text] [Related]  

  • 39. [Definition of the drug given in 1969 by a committee of WHO experts].
    Quevauviller A; Mabileau J; Vaille C
    Ann Pharm Fr; 1969 Jun; 27(6):403-9. PubMed ID: 5392371
    [No Abstract]   [Full Text] [Related]  

  • 40. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.
    World Health Organization
    World Health Organ Tech Rep Ser; 2007; (943):1-156. PubMed ID: 17621973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.